Home > Insider Trading > Filing (0001209191-18-024986)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
908259	Mateon Therapeutics Inc	MATN	Biological Products, (No Disgnostic Substances) (2836)	133679168

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1236260	M Matthew Loar	C/O Mateon Therapeutics, Inc. 701 Gateway Blvd., Suite 210 South San Francisco CA 94080	Chief Financial Officer	No	Yes	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2018-04-12	250,000	$0.00	300,000	No	4	P	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	P	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Common Stock A Warrant (Right to Buy)	Acquisiton	2018-04-12	125,000	$0.00	125,000	$0.40
Common Stock	Common Stock B Warrant (Right to Buy)	Acquisiton	2018-04-12	125,000	$0.00	125,000	$0.40

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
125,000	2018-04-12	2020-04-12	No	4	P	Direct
125,000			No	4	P	Direct

Footnotes

The reported securities are included within one Unit purchased by the reporting person for $50,000 per Unit pursuant to a Subscription Agreement between the reporting person and Mateon Therapeutics, Inc. (the "Company"), dated April 12, 2018 (the "Subscription Agreement"). Each Unit consists of (i) 250,000 shares of Common Stock of the Company, par value $0.01 per share (the "Common Stock"), (ii) an "A" warrant to purchase 125,000 shares of Common Stock at an exercise price of $0.40 per share and (iii) a "B" warrant to purchase 125,000 shares of Common Stock at an exercise price of $0.40 per share.
The Common Stock B Warrants shall become exercisable immediately following the Company's stockholders' approval of an increase in the number of the Company's authorized shares of Common Stock sufficient to cover the number of shares issuable upon the exercise of all of the Common Stock B Warrants (the "Stock Authorization"). The Company is obligated to effect the Stock Authorization no later than June 30, 2018 (the "Authorization Date").
The Common Stock B Warrants shall expire on the date that is two years after the Stock Authorization is effected (the "Expiration Date"). In the event that the Company fails to effect the Stock Authorization by the Authorization Date, the Expiration Date will be extended for two additional years.